TY - JOUR T1 - Disease burden of chronic hepatitis C in Brazil JO - The Brazilian Journal of Infectious Diseases T2 - AU - Ferreira,Paulo Roberto Abrão AU - Brandão-Mello,Carlos Eduardo AU - Estes,Chris AU - Júnior,Fernando Lopes Gonçales AU - Coelho,Henrique Sérgio Moraes AU - Razavi,Homie AU - Cheinquer,Hugo AU - Wolff,Fernando Herz AU - Ferraz,Maria Lúcia Gomes AU - Pessoa,Mário Guimarães AU - Mendes-Correa,Maria Cássia SN - 14138670 M3 - 10.1016/j.bjid.2015.04.004 DO - 10.1016/j.bjid.2015.04.004 UR - https://bjid.org.br/en-disease-burden-chronic-hepatitis-c-articulo-S1413867015000951 AB - BackgroundHepatitis C virus infection is a major cause of cirrhosis; hepatocellular carcinoma; and liver transplantation. The aim of this study was to estimate hepatitis C virus disease progression and the burden of disease from a nationwide perspective. MethodsUsing a model developed to forecast hepatitis C virus disease progression and the number of cases at each stage of liver disease; hepatitis C virus-infected population and associated disease progression in Brazil were quantified. The impact of two different strategies was compared: higher sustained virological response and treatment eligibility rates (1) or higher diagnosis and treatment rates associated with increased sustained virological response rates (2). ResultsThe number of infected individuals is estimated to decline by 35% by 2030 (1,255,000 individuals); while the number of cases of compensated (n=325,900) and decompensated (n=45,000) cirrhosis; hepatocellular carcinoma (n=19,100); and liver-related deaths (n=16,700) is supposed to peak between 2028 and 2032. In strategy 2; treated cases increased over tenfold in 2020 (118,800 treated) as compared to 2013 (11,740 treated); with sustained virological response increased to 90% and treatment eligibility to 95%. Under this strategy; the number of infected individuals decreased by 90% between 2013 and 2030. Compared to the base case; liver-related deaths decreased by 70% by 2030; while hepatitis C virus-related liver cancer and decompensated cirrhosis decreased by 75 and 80%; respectively. ConclusionsWhile the incidence and prevalence of hepatitis C virus in Brazil are decreasing; cases of advanced liver disease continue to rise. Besides higher sustained virological response rates; new strategies focused on increasing the proportion of diagnosed patients and eligibility to treatment should be adopted in order to reduce the burden of hepatitis C virus infection in Brazil. ER -